Remdesivir

Evidence Level: L5

Predicted Indications: 6

Remdesivir

Pharmacist Assessment Report

Remdesivir: From an Unspecified Original Indication to Multiple Endocrine Neoplasia

One-Sentence Summary

Remdesivir is a nucleotide analog antiviral that inhibits viral RNA polymerase and is marketed in India as an injectable product. The TxGNN model predicts it may be effective for multiple endocrine neoplasia, but there are 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone and the evidence is weak.

Quick Overview

Item	Content
Original Indication	Not stated in the Indian licence records compiled for this report
Predicted New Indication	Multiple endocrine neoplasia
TxGNN Prediction Score	0.9950
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (5 of 5) – CDSCO approval status is not included in this data
Number of Listed Products	5 (valid: 5)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. From general knowledge, remdesivir is a nucleotide analog prodrug that inhibits viral RNA-dependent RNA polymerase, and its established use is against RNA viruses such as SARS-CoV-2.

Multiple endocrine neoplasia is a hereditary tumour syndrome (for example, MEN1 or RET mutations). Remdesivir has no known target in its pathophysiology, so no plausible mechanistic link can be identified. The high TxGNN score appears to be a TxGNN model (deep learning) artefact rather than a pharmacological signal. No supporting trials or literature were found.

Other predictions were also reviewed. The most biologically plausible, HIV infection (score 0.9932, L4), has only a theoretical rationale. Remdesivir is not an established antiretroviral, and the retrieved literature concerns COVID-19, not HIV. The remaining predictions (simian immunodeficiency virus infection, feline AIDS, homozygous familial hypercholesterolaemia, Prinzmetal angina, leprosy, antithrombin deficiency type 2, a rare neurodevelopmental disorder, and cytomegalovirus infection) also lack a convincing mechanism or direct evidence.

Clinical Trial Evidence

Currently no related clinical trials are registered for multiple endocrine neoplasia.

For reference, one trial was retrieved for the second-ranked prediction (HIV infection). It is only weakly relevant:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04385719	Phase 2	Completed	24	Pharmacokinetic study in healthy Ugandan volunteers of how tenofovir/lamivudine or atazanavir/ritonavir affect remdesivir blood levels. It does not assess efficacy in HIV.

Literature Evidence

Currently no related literature is available for multiple endocrine neoplasia.

For the HIV-infection prediction, the retrieved publications are almost all about COVID-19 and are not direct evidence for HIV. The most notable are:

PMID	Year	Type	Journal	Key Findings
33264556	2021	RCT	N Engl J Med	Interim WHO Solidarity trial of repurposed antivirals, including remdesivir, in hospitalised COVID-19
38675889	2024	RCT	Viruses	No remdesivir resistance observed in the Phase 3 SIMPLE trials in severe and moderate COVID-19
34696838	2021	Review	The Enzymes	Mechanisms of nucleotide analogs inhibiting viral RNA replication, comparing SARS-CoV-2 RdRp with HIV reverse transcriptase
36347057	2022	Review	Topics in Antiviral Medicine	CROI 2022 update on antiviral advances for HIV, COVID-19 and viral hepatitis

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
189883	Remdiz 100mg Injection (Glenmark Pharmaceuticals Ltd)	Vial of 1 injection	Not stated
187652	Remwin 100mg Injection (Sun Pharmaceutical Industries Ltd)	Vial of 1 injection	Not stated
185844	Remdac Injection (Zydus Cadila)	Vial of 1 injection	Not stated
35394	Cipremi Injection (Cipla Ltd)	Vial of 1 injection	Not stated
60746	Desrem Injection (Mylan Pharmaceuticals Pvt Ltd)	Vial of 1 injection	Not stated

All five registrations are valid single-ingredient products, and all are injectables.

Safety Considerations

Drug Interactions: The interaction screening returned 100 interactions in total. The 20 retrieved are all rated Moderate, including:

Antibiotics: doxycycline, minocycline, tetracycline, clarithromycin, levofloxacin, vancomycin, kanamycin, neomycin
Antifungals: amphotericin B (including the lipid complex)
Antidiabetics: acarbose, pioglitazone
Aminosalicylates: mesalazine, balsalazide, olsalazine
Others: bupropion, naltrexone, chenodeoxycholic acid, oxandrolone, oxymetholone

For other warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The multiple endocrine neoplasia prediction has no clinical trial or literature support (L5) and no plausible mechanistic link to a viral polymerase inhibitor. The high TxGNN score alone does not justify further investment.

To proceed, the following is needed:

Package insert warnings and contraindications from the Indian regulator or manufacturers
Mechanism of action data from DrugBank
Original approved indication text for the Indian licences
Preclinical or mechanistic evidence linking remdesivir to MEN-related pathways, if this indication is to be pursued
Alternatively, redirect evaluation to a more plausible antiviral indication, such as HIV infection, with direct efficacy data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.